Luke Hartnett
About Luke Hartnett
Luke Hartnett is an Associate Director of CMC Management at Prothena Corporation Plc, with extensive experience in quality control and drug development across various pharmaceutical companies. He holds an MBA from the University of Edinburgh and a Bachelor of Science in Chemistry from the University of Greenwich.
Work at Prothena
Luke Hartnett has been serving as Associate Director of CMC Management at Prothena Corporation Plc since 2016. His role involves overseeing the chemistry, manufacturing, and controls aspects of drug development. He has contributed to the advancement of therapeutic candidates within the organization while ensuring compliance with regulatory standards. Prothena is known for its focus on developing novel therapies for neurodegenerative diseases.
Education and Expertise
Luke Hartnett holds a Master of Business Administration from the University of Edinburgh School of Philosophy, Psychology and Language Sciences, which he completed from 2011 to 2012. He also earned a Bachelor of Science in Chemistry from the University of Greenwich in 1998. His educational background provides a strong foundation for his roles in drug development and quality control within the pharmaceutical industry.
Background
Luke Hartnett began his career as an R&D Analyst at Clonmel Healthcare Limited from 1999 to 2001. He then transitioned to various roles in quality control and management at companies such as Pfizer, NPS Pharmaceuticals, and Merck. His experience spans multiple facets of the pharmaceutical industry, including quality assurance and drug development, which has shaped his current position in CMC Management.
Professional Experience
Before joining Prothena, Luke Hartnett worked at NPS Pharmaceuticals as Associate Director of QC - International from 2014 to 2016. He also had a brief tenure as Senior QC Manager at Amgen in 2014. His previous roles include a position as QC Technologies Supervisor at Pfizer from 2006 to 2011, where he gained significant experience in quality control processes.
Current Role at Strongbridge Biopharma
Since 2018, Luke Hartnett has held the position of Director of Drug Development and Manufacturing at Strongbridge Biopharma Plc. In this role, he is responsible for overseeing the development and manufacturing processes of pharmaceutical products, ensuring they meet industry standards and regulatory requirements. His leadership in this area contributes to the company's mission of advancing innovative therapies.